In This Article:
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at ChromaDex (CDXC), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. ChromaDex currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?
In order to see if CDXC is a promising momentum pick, let's examine some Momentum Style elements to see if this natural products company holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For CDXC, shares are up 68.88% over the past week while the Zacks Medical - Biomedical and Genetics industry is down 0.75% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 96.8% compares favorably with the industry's 5.78% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of ChromaDex have increased 105.46% over the past quarter, and have gained 376.76% in the last year. In comparison, the S&P 500 has only moved 15.2% and 38.09%, respectively.
Investors should also take note of CDXC's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, CDXC is averaging 2,538,904 shares for the last 20 days.